Azitra Inc (AZTR)

Azitra, Inc.'s stock has experienced significant declines over the past year. Key events impacting the stock include Azitra denying a report of a $44 million direct offering, announcing its Q3 2025 results and providing business updates, announcing the pricing of a $1.5 million private placement, receiving NYSE American approval for its listing compliance plan, and adjourning a special meeting of stockholders due to a lack of quorum. The stock price has fluctuated between $0.20 and $2.97 over the past year.

Azitra, Inc.'s products and services are not typically subject to the same demand seasonality as consumer goods. Demand for its products, once approved, would primarily be driven by the prevalence of the conditions they treat and the medical community's adoption of these therapies. The development of consumer products in collaboration with Bayer might introduce some seasonality, but the core biopharmaceutical pipeline is unlikely to be significantly affected by seasonal consumer trends.

Azitra, Inc. is a clinical biopharmaceutical company focused on developing advanced therapies for precision dermatology, operating within the biotechnology industry. They leverage their scientific knowledge to develop novel products for treating various adverse skin conditions and diseases. Their product pipeline includes ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor-associated rash, and ATR-01 for ichthyosis vulgaris. The company also has a joint development program with Bayer for skincare products and a microbial library of approximately 1,500 unique bacterial strains.

Azitra, Inc. is headquartered in Branford, Connecticut, United States. Founded in 2014, the company employs 12 full-time employees. While its development efforts are based in the U.S., its focus on developing therapies for various skin conditions suggests a potential global market.

Azitra, Inc.'s brand reputation appears to be significantly influenced by its stock performance and operational developments. The substantial decrease in stock price suggests a challenging period for investor confidence. News events such as the denial of a direct offering report and the adjournment of a special meeting could negatively impact public perception. However, the company's collaboration with Bayer and its focus on developing therapies for unmet medical needs in dermatology could contribute positively to its scientific and medical reputation.

Azitra, Inc. has 8 institutional owners and shareholders holding a total of 42,284 shares, including Geode Capital Management, LLC, National Bank Of Canada, UBS Group AG, Tower Research Capital LLC, and Bank Of America Corp. Alumni Capital Management and Alumni Capital LP each hold 4.99% of the company's shares, and Bayer Aktiengesellschaft holds 0.07% of the shares. Co-founder Travis Whitfill, CEO Francisco Salva, and CFO Norman Staskey have made recent stock purchases.